Program in Cancer Biology

Research Description

Dr. Short’s research focus has shifted to the role glutathione peroxidase 1 (GPx1). GPx1 is one of the most widely expressed antioxidant proteins in the body, yet its role in the intestine is largely unknown. Interestingly, while antioxidant proteins are mostly thought to protect the intestine in the setting of inflammatory bowel disease and colitis-associated cancer, Dr. Short’s preliminary data show that mice without GPx1 are protected from colitis. Her research aims to more accurately define how GPx1, antioxidant systems, and ROS contribute to intestinal homeostasis and disease, as well as evaluate whether these pathways can be targeted in the setting of gastrointestinal disease. Dr. Short’s career goal is to run an independent laboratory as a tenure-track faulty member, and she is currently funded by a K01 award from the National Institute of Diabetes and Digestive and Kidney Diseases, the Crohn’s and Colitis Foundation, and the American Gastroenterological Association to aid this transition.

Publications

Reddy VK, Short SP, Barrett CW, Mittal MK, Keating CE, Thompson JJ, Harris EI, Revetta FL, Bader DM, Brand T, M. Kay Washington MK, Williams CS. BVES Regulates Intestinal Stem Cell Programs and Intestinal Crypt Viability after Radiation. Stem Cells. 2016; 34(6):1626-36. PMICD: PMC4893006

Parang B, Bradley AM, Mittal MK, Short SP, Thompson JJ, Barrett CW, Naik RD, Bilotta AJ,Washington MK, Revetta FL, Smith JJ, Chen X, Wilson KT, Hiebert SW, Williams CS. Myeloid translocation genes differentially regulate colorectal cancer programs. Oncogene. 2016; 35(49): 6341-6349. PMCID:PMC5140770

Barrett CW, Short SP, Williams CS. Selenoproteins and oxidative stress-induced inflammatory tumorigenesis in the gut. Cell Mol Life Sci. 2016; 74(4): 607-616. PMCID: PMC5274549

Barrett CW, Short SP, Choksi YA, Williams CS. Whole-mount Enteroid Proliferation Staining. Bio-protocol. 2016; 6(12): e1837. PMCID: PMC5760989

Wang C, Gong G, Sheh A, Muthupalani S, Bryant EM, Puglisi DA, Holcombe H, Conaway EA, Parry NA, Bakthavatchalu V, Short SP, Williams CS, Wogan GN, Tannenbaum SR, Fox JG, and Horwitz BH. Interleukin-22 drives nitric oxide-dependent DNA damage and dysplasia in a murine model of colitis-associated cancer. Mucosal Immunol. 2017; 10(6):1504-1517. PMCID: PMC5557711Short SP, Costacurta PW, Williams CS. Using 3D Organoid Cultures to Model Intestinal Physiology and Colorectal Cancer. Curr Colorectal Cancer Rep. 2017: 13:183-191. PMCID: PMC5736147

Parang B, Kaz AM, Barrett CW, Short SP, Ning W, Keating CE, Mittal MK, Naik RD, Washington MK, Revetta FL, Smith JJ, Chen X, Wilson KT, Brand T, Bader DM, Tansey WP, Chen R, Brentnall TA, Grady WM, Williams CS. BVES regulates c-Myc stability via PP2A and suppresses colitis-induced tumourigenesis. Gut. 2017; 66(5): 852-862. PMCID: PMC5385850

McDonough EM, Barrett CW, Parang B, Mittal MK, Smith JJ, Bradley AM, Choksi YA, Coburn LA, Short SP, Thompson JJ, Zhang B, Poindexter SV, Fischer MA, Chen X, Li J, Revetta FL, Naik RD, Washington MK, Rosen MJ, Hiebert SW, Wilson KT, Williams CS. MTG16 is a tumor suppressor in colitis-associated carcinoma. JCI insight, 2017; 2(16): 78210. PMCID: PMC5621889

Short SP and Williams CS. Selenoproteins in tumorigenesis and cancer progression. Adv Cancer Res. 2017: 136:49-83.

Short SP, Kondo J, Smalley-Freed WG, Takeda H, Dohn MR, Powell AE, Carnahan RH, Washington MK, Tripathi M, Payne DM, Jenkins NA, Copeland NG, Coffey RJ, Reynolds AB. p120 is an obligate haploinsufficient tumor suppressor in intestinal neoplasia. JCI, 2017; 127(12):4462–4476. Co-first author.